Vani Reddi, MD
Internal Medicine · North Andover, MANPI 1407803299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 517 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,129 and has fallen 54.8% since, to $1,413 in 2025. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- Pfizer$1K
- Amgen$888
- AbbVie$793
- plus $4K from 33 others
What the payments were for
- Food & beverage$11,46899%
- Education$1221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $1,984 |
| Novo Nordisk | 57 | $1,702 |
| Boehringer Ingelheim | 56 | $1,290 |
| Pfizer | 69 | $1,230 |
| Amgen | 30 | $888 |
| AbbVie | 42 | $793 |
| Lilly USA, LLC | 32 | $582 |
| Merck | 23 | $403 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $323 |
| GSK | 10 | $251 |
| Novartis | 10 | $200 |
| Exact Sciences | 8 | $194 |
| Radius Health, Inc. | 5 | $184 |
| Paratek Pharmaceuticals, Inc. | 5 | $178 |
| Amarin Pharma, Inc. | 17 | $153 |
| Johnson & Johnson | 3 | $151 |
| E.r. Squibb & Sons, L.L.C. | 6 | $125 |
| Astellas Pharma US Inc | 6 | $118 |
| Ironshore Pharmaceuticals Inc. | 1 | $107 |
| Bayer | 5 | $102 |
| Currax Pharmaceuticals LLC | 6 | $93 |
| Esperion Therapeutics, Inc. | 3 | $80 |
| Biohaven Pharmaceuticals, Inc. | 3 | $66 |
| Genentech USA, Inc. | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Eisai Inc. | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Neos Therapeutics, LP | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
| Echosens North America, Inc. | 1 | $13 |
| Avion Pharmaceuticals | 1 | $12 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,590 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $53,589 |
| XareltoRivaroxaban | 21 | $24,606 |
| EliquisApixaban | 20 | $24,327 |
| JanuviaSitagliptin Phosphate | 31 | $23,167 |
| FarxigaDapagliflozin Propanediol | 13 | $16,141 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,208 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $4,819 |
| Atorvastatin Calcium | 326 | $4,279 |
| Metoprolol Succinate | 240 | $4,202 |
| Rosuvastatin Calcium | 175 | $3,584 |
| Amlodipine Besylate | 340 | $2,733 |
| Losartan Potassium | 239 | $2,569 |
| Ezetimibe | 43 | $1,852 |
| Pravastatin Sodium | 65 | $1,669 |
| Levothyroxine Sodium | 182 | $1,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,702 | $53,58958 claims |
| Johnson & JohnsonXarelto | $151 | $24,60621 claims |
| PfizerEliquis | $1,230 | $24,32720 claims |
| MerckJanuvia | $403 | $23,16731 claims |
| AstraZenecaFarxiga | $1,984 | $16,14113 claims |
| GSKBreo Ellipta | $251 | $6,20813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in North Andover
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.